



1725 I Street NW • Suite 510 • Washington, DC 20006  
Tel 202-659-0599 • Fax 202-659-0709 • [www.asn-online.org](http://www.asn-online.org)

## **EMBARGOED FOR RELEASE UNTIL 5:00 PM ET ON APRIL 1, 2009**

**Contact:** Shari Leventhal: 202-416-0658, [sleventhal@asn-online.org](mailto:sleventhal@asn-online.org)

### **PROCEDURE IMPROVES HEALTH OF CANCER PATIENTS**

*When Used in Combination with Chemotherapy, Hemodialysis Procedure Extends Lifespan*

**Washington, DC (Friday, March 27, 2009)** — A novel hemodialysis procedure helps restore kidney function and increases lifespan in patients with multiple myeloma, according to a study appearing in the April 2009 issue of the *Clinical Journal of the American Society Nephrology* (CJASN).

Multiple myeloma is a form of cancer that causes severe kidney failure. Once multiple myeloma patients require dialysis to treat their kidney failure, most live less than a year. Unfortunately, there are no effective treatments to help these cancer patients.

However, researchers have suspected that a procedure called high cut-off hemodialysis, which removes large immunological proteins that cause kidney damage in myeloma patients, might improve patients' health and allow them to live longer (when used in combination with chemotherapy). To test high cut-off hemodialysis' potential, Colin Hutchison, MD (University Hospital Birmingham, United Kingdom), and his colleagues studied 19 individuals with multiple myeloma who underwent the procedure while receiving chemotherapy. Thirteen of the 19 patients completed the full treatment protocol, and in all 13 immunological proteins were reduced. In addition, kidney function was restored in all 13 patients.

“This study saw over 70% of patients becoming independent of dialysis, which is greatly above the rate expected in this setting,” said Dr. Hutchison. “High cut-off hemodialysis is exciting because it offers a novel way of treating this group of patients who have historically done very poorly,” he added.

The study was a pilot study and therefore not controlled. Thus, it cannot be used to change medical practice. The EuLITE trial (European trial of free light chain removal by extended haemodialysis) is a randomized control trial designed to further evaluate this treatment.

Dr Hutchison has received speaker honorarium and travel expenses from Gambro. Co-authors Mark Cook, MD, and Paul Cockwell, MD (University Hospital Birmingham), report no financial disclosures.

**MORE**

---

The article, entitled “Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis,” will appear online at <http://cjasn.asnjournals.org/> on Wednesday, April 1, 2009, doi 10.2215/CJN.04590908.

Founded in 1966, the American Society of Nephrology (ASN) is the world’s largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians.

###